A clinical trial update was posted on November 13, 2026 concerning a study relevant to gonadorelin related treatment pathways in prostate cancer. The trial, titled "TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)," is registered under identifier NCT07190300.
The study is listed as Phase I/II and its current status is recruiting. It is designed as an open-label trial comparing tulmimetostat combined with darolutamide against darolutamide alone, as well as tulmimetostat combined with abiraterone, in patients with metastatic hormone-sensitive prostate cancer.
No outcome or efficacy data have been reported as part of this update. The listing reflects recruitment status only, as recorded on the trial registry as of the stated date. Further information, including eligibility criteria and trial design details, can be found through the official registry listing.
Readers interested in background on gonadorelin, including its approved uses and mechanism, can consult the compound overview for additional context.